The palivizumab patchwork: Variation in guidelines for Respiratory Syncytial Virus prevention across Canadian provinces and territories
Bibliographic record
Abstract
Background: Respiratory Syncytial Virus is the leading cause of hospitalization for lower respiratory tract infection in young children. The only preventive intervention is an anti-Respiratory Syncytial Virus (RSV) monoclonal antibody (palivizumab, Synagis) administered as monthly intramuscular injections during the winter. Recommendations for palivizumab use have been published by the Canadian Paediatric Society (CPS) and other agencies. We sought to determine if there was interjurisdictional variation in eligibility for palivizumab across provinces and territories and in comparison to CPS recommendations, as well as the nature of this variation. Methods: Eligibility criteria were obtained from personnel coordinating provincial and territorial programs and from public governmental websites. Results: All 13 jurisdictions provided information about their palivizumab eligibility policies. No province or territory (PT) follows CPS guidelines exactly and substantial heterogeneity exists among jurisdictions. All PT jurisdictions provide prophylaxis in the first year of life to infants with hemodynamically significant congenital heart disease or chronic lung disease on ongoing therapy for those conditions, and to premature children in remote areas. In general, PTs had more liberal policies than the CPS, offering palivizumab to a wide range of children with conditions such as cystic fibrosis, Down syndrome or to moderately premature children with risk factors. Conclusions: Substantial variation in PT criteria for RSV prevention exists in Canada, and no jurisdiction follows CPS criteria exactly. Variability in subnational policy may reflect access to human or material resources, varying interpretation of evidence for efficacy, variation in epidemiology, the effect of local pressures, or advocacy.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.011 | 0.034 |
| Meta-epidemiology (narrow) | 0.000 | 0.001 |
| Meta-epidemiology (broad) | 0.000 | 0.001 |
| Bibliometrics | 0.003 | 0.007 |
| Science and technology studies | 0.005 | 0.002 |
| Scholarly communication | 0.003 | 0.001 |
| Open science | 0.004 | 0.002 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".